PAR paradigm biopharmaceuticals limited..

Trial PAR008 is on ANZCTR, page-2

  1. 4,896 Posts.
    lightbulb Created with Sketch. 7614
    Nice one...
    Good to see an increase in number of Biomarkers to be observed, namely (but not necessarily limited to):

    • COMP
    • C terminal telopeptide (CTX) -II
    • NGF, interleukin (IL) -1ß,
    • TNFa,
    • IL-6
    • A disintegrin and metalloproteinase with thrombospondin motif 5 (ADAMTS-5),
    • ARGS (aggrecan cleavage fragments)
    • Tissue inhibitor matrix metalloproteinase 1 (TIMP-1)
    • CTX-I
    • Type II collagen (C2C)


    Quite a comprehensive study also looking at Pain, Function and Stiffness along with Serum samples.
    Will be illustrative to get a comparison between Synovium and Serum activity and the effects of iPPS on each.
    Last edited by Mozzarc: 12/02/21
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
43.0¢
Change
-0.005(1.15%)
Mkt cap ! $170.8M
Open High Low Value Volume
43.5¢ 43.5¢ 40.5¢ $532.2K 1.265M

Buyers (Bids)

No. Vol. Price($)
1 4500 41.5¢
 

Sellers (Offers)

Price($) Vol. No.
43.0¢ 9422 3
View Market Depth
Last trade - 16.10pm 10/07/2025 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.